Getting medicines to those who need them most

We recognize that the patients and families who battle life-threatening diseases anxiously await more effective medicines with each passing day. Knowing this drives us to work harder, to deliver transformative treatments more swiftly.

We also seek to ensure any medicine we develop is safe and effective and follows the rigorous guidelines established by regulatory agencies.

We strive to balance these two complementary and vital goals in all that we do.

To learn more about our clinical trials, visit blueprintclinicaltrials.com or contact us in the U.S. at medinfo@blueprintmedicines.com or 1-888-BLU-PRNT (1-888-258-7768), and in Europe at medinfoeurope@blueprintmedicines.com or +31 85 064 4001.

Our clinical trials

Our clinical trials in

Systemic mastocytosis (SM)

Pathfinder

A clinical trial for people with advanced systemic mastocytosis

Trial Phase

Trial Phase 2

Target Population

Target Population

Aggressive SM, SM with associated hematologic neoplasm, and mast cell leukemia

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT03580655

Learn more: blueprintclinicaltrials.com/pathfinder or clinicaltrials.gov/ct2/show/NCT03580655

Pioneer

A clinical trial for people with indolent or smoldering systemic mastocytosis

Trial Phase

Trial Phase 2

Target Population

Target Population

Indolent SM and smoldering SM

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT03731260

Learn more: blueprintclinicaltrials.com/pioneer or clinicaltrials.gov/ct2/show/NCT03731260

Our clinical trials in

RET-altered cancers

Arrow

A clinical trial for people with RET-altered cancers

Trial Phase

Trial Phase 1/2

Target Population

Target Population

RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) or other solid tumors with a RET fusion or mutation

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT03037385

Learn more: blueprintclinicaltrials.com/arrow or clinicaltrials.gov/ct2/show/NCT03037385

AcceleRET Lung

A clinical trial for people with RET fusion-positive, metastatic non-small cell lung cancer (NSCLC)

Trial Phase

Trial Phase 3

Target Population

Target Population

First-line RET fusion-positive, metastatic NSCLC

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT04222972

Learn more: https://www.clinicaltrials.gov/ct2/show/NCT04222972

Our clinical trials in

Hepatocellular carcinoma (HCC)

FISOGATINIB + SUGEMALIMAB (CS1001)

A clinical trial for people with hepatocellular carcinoma

Trial Phase

Trial Phase 1b/2

Target Population

Target Population

Locally advanced or metastatic HCC; conducted in China

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT04194801

Learn more: clinicaltrials.gov/ct2/show/NCT04194801